Logo image of SKIN

BEAUTY HEALTH CO/THE (SKIN) Stock Fundamental Analysis

USA - NASDAQ:SKIN - US88331L1089 - Common Stock

1.43 USD
0 (0%)
Last: 10/20/2025, 2:55:42 PM
Fundamental Rating

2

Overall SKIN gets a fundamental rating of 2 out of 10. We evaluated SKIN against 33 industry peers in the Personal Care Products industry. While SKIN seems to be doing ok healthwise, there are quite some concerns on its profitability. SKIN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SKIN has reported negative net income.
In the past year SKIN had a positive cash flow from operations.
In the past 5 years SKIN reported 4 times negative net income.
In multiple years SKIN reported negative operating cash flow during the last 5 years.
SKIN Yearly Net Income VS EBIT VS OCF VS FCFSKIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -3.74%, SKIN is doing worse than 66.67% of the companies in the same industry.
Looking at the Return On Equity, with a value of -25.68%, SKIN is doing worse than 69.70% of the companies in the same industry.
Industry RankSector Rank
ROA -3.74%
ROE -25.68%
ROIC N/A
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKIN Yearly ROA, ROE, ROICSKIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

SKIN has a Gross Margin (63.21%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SKIN has declined.
SKIN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
SKIN Yearly Profit, Operating, Gross MarginsSKIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SKIN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, SKIN has a worse debt to assets ratio.
SKIN Yearly Shares OutstandingSKIN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
SKIN Yearly Total Debt VS Total AssetsSKIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.18, we must say that SKIN is in the distress zone and has some risk of bankruptcy.
SKIN has a Altman-Z score of -0.18. This is amonst the worse of the industry: SKIN underperforms 87.88% of its industry peers.
The Debt to FCF ratio of SKIN is 10.75, which is on the high side as it means it would take SKIN, 10.75 years of fcf income to pay off all of its debts.
SKIN has a better Debt to FCF ratio (10.75) than 60.61% of its industry peers.
SKIN has a Debt/Equity ratio of 4.91. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SKIN (4.91) is worse than 87.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.91
Debt/FCF 10.75
Altman-Z -0.18
ROIC/WACCN/A
WACC5.76%
SKIN Yearly LT Debt VS Equity VS FCFSKIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

SKIN has a Current Ratio of 5.15. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SKIN (5.15) is better than 93.94% of its industry peers.
A Quick Ratio of 4.15 indicates that SKIN has no problem at all paying its short term obligations.
SKIN has a Quick ratio of 4.15. This is amongst the best in the industry. SKIN outperforms 93.94% of its industry peers.
Industry RankSector Rank
Current Ratio 5.15
Quick Ratio 4.15
SKIN Yearly Current Assets VS Current LiabilitesSKIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for SKIN have decreased strongly by -1147.62% in the last year.
SKIN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.33%.
The Revenue has been growing by 8.72% on average over the past years. This is quite good.
EPS 1Y (TTM)-1147.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2900%
Revenue 1Y (TTM)-15.33%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-13.69%

3.2 Future

Based on estimates for the next years, SKIN will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.76% on average per year.
Based on estimates for the next years, SKIN will show a small growth in Revenue. The Revenue will grow by 2.41% on average per year.
EPS Next Y31.62%
EPS Next 2Y19.43%
EPS Next 3Y11.15%
EPS Next 5Y19.76%
Revenue Next Year-10.5%
Revenue Next 2Y-2.77%
Revenue Next 3Y-0.66%
Revenue Next 5Y2.41%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SKIN Yearly Revenue VS EstimatesSKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2032 100M 200M 300M 400M 500M
SKIN Yearly EPS VS EstimatesSKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SKIN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKIN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKIN Price Earnings VS Forward Price EarningsSKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, SKIN is valued cheaply inside the industry as 93.94% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 5.37
EV/EBITDA N/A
SKIN Per share dataSKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.43%
EPS Next 3Y11.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SKIN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAUTY HEALTH CO/THE

NASDAQ:SKIN (10/20/2025, 2:55:42 PM)

1.43

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners85.29%
Inst Owner Change-0.48%
Ins Owners10.05%
Ins Owner Change12.12%
Market Cap181.37M
Analysts51.43
Price Target2.3 (60.84%)
Short Float %14.65%
Short Ratio14.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.76%
Min EPS beat(2)37.88%
Max EPS beat(2)155.64%
EPS beat(4)4
Avg EPS beat(4)60.34%
Min EPS beat(4)20.82%
Max EPS beat(4)155.64%
EPS beat(8)8
Avg EPS beat(8)57.58%
EPS beat(12)11
Avg EPS beat(12)64.71%
EPS beat(16)13
Avg EPS beat(16)-299.56%
Revenue beat(2)2
Avg Revenue beat(2)4.92%
Min Revenue beat(2)2.9%
Max Revenue beat(2)6.94%
Revenue beat(4)4
Avg Revenue beat(4)5.03%
Min Revenue beat(4)2.9%
Max Revenue beat(4)6.94%
Revenue beat(8)5
Avg Revenue beat(8)-0.02%
Revenue beat(12)7
Avg Revenue beat(12)0.21%
Revenue beat(16)11
Avg Revenue beat(16)3.62%
PT rev (1m)18.42%
PT rev (3m)27.84%
EPS NQ rev (1m)-6.32%
EPS NQ rev (3m)-15.45%
EPS NY rev (1m)21.05%
EPS NY rev (3m)45.1%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF 5.37
P/OCF 4.6
P/B 2.45
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)0.27
FCFY18.62%
OCF(TTM)0.31
OCFY21.74%
SpS2.44
BVpS0.58
TBVpS-0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.74%
ROE -25.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.21%
FCFM 10.89%
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 4.91
Debt/FCF 10.75
Debt/EBITDA N/A
Cap/Depr 24.4%
Cap/Sales 1.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.15
Quick Ratio 4.15
Altman-Z -0.18
F-Score6
WACC5.76%
ROIC/WACCN/A
Cap/Depr(3y)42.98%
Cap/Depr(5y)45.87%
Cap/Sales(3y)3.35%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1147.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2900%
EPS Next Y31.62%
EPS Next 2Y19.43%
EPS Next 3Y11.15%
EPS Next 5Y19.76%
Revenue 1Y (TTM)-15.33%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-13.69%
Revenue Next Year-10.5%
Revenue Next 2Y-2.77%
Revenue Next 3Y-0.66%
Revenue Next 5Y2.41%
EBIT growth 1Y56.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.27%
EBIT Next 3Y34.01%
EBIT Next 5Y34.66%
FCF growth 1Y172.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y241.68%
OCF growth 3YN/A
OCF growth 5YN/A